

Pharmaceuticals & Biotechnology

Key data	
Price (DKK)	0.18
Country	Denmark
Bloomberg	PEGA DC
Reuters	PEGRP.CO
Free float	100.0%
Market cap (DKKm)	221
Net debt (current Y/E) (DKKm)	-11
No. of shares (m)	1,227.5
Next event	Q4: 31-Mar

* Price as at 12:30 CET on 15 November 2024

CEO Thomas Kaas Selsø CFO

Company description

Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With a focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.

Omauthorized redistributio	ture		
5 Finansmanageme	ent ApS		16.6%
Z DMZ Holding ApS			7.6%
dn			
0.0			
ty 0			
Source: Compar	nv data		
ш, к			
in the second se			
Source: Compar	25		
© Sales Selection (adj.) EBIT (adj.) EPS (adj.)	24E	25E	26E
Sales		0.0%	0.0%
S EBITDA	n.m.	n.m.	-5.3%
EBIT (adj.)	n.m.	n.m.	-5.2%
EPS (adj.)	n.m.	n.m.	n.m.
ESource: Danske	Bank Equity	Research	estimates
or	Dann Equity	Resources	00000000

Analyst(s)

Thomas Bowers

Tobias Nissen

Find our research here: https://research.danskebank.com

Important disclosures and certifications are contained from page 12 of this report

Pharma Equity Group

Gearing up for a partnership in 2025

PEG reported an uneventful Q3, which was in line with our expectations. Our focus remains on 2025, where the company is gearing up to secure a potential partnership for RNX-011/RNX-051, which we find crucial for the shares. The funding overhang has been resolved with the DKK51m capital raise in October. Our SoTP now points to a fair value range of DKK0.30-0.76 per share (was DKK0.31-0.77).

- Pipeline and company update. The Q3 24 report included no updates to the pipeline, and we expect the next data readout to be RNX-041 pouchitis in Q2 25. In October, Reponex was granted a patent for RNX-051 in Japan, valid until 2039, with the company already having secured patent protection in Europe. The capital raise of DKK51m has removed the short-term funding overhang in the shares until a partner is secured. The company is still pre-revenue and cash burning (c.DKK2m per month), and we model a cumulative cash burn of c.DKK12m before turning cash flow positive by 2028E. We see the capital raise and further patent protection as a positive step for PEG, but we also see significant risks related to clinical development and patents, and risk of delays in securing a partnering agreement.
- Investment case. PEG repositions drugs for new and innovative purposes, which cuts the time-to-market by several years and reduces R&D costs dramatically, but at the expense of weaker patent rights. PEG has ramped up efforts to find a larger pharma partner for the key assets, RNX-011 and RNX-051, before the end of 2025 in return for upfront, milestones and sales-based royalties. PEG is in dialogue with key opinion leaders to explore cooperation and secure feedback, which will be used to approach selected companies for a partnership.
- Estimate changes. We make small changes to our model, slightly lifting SG&A costs. We still forecast the potential launch of the key pipeline assets RNX-011 and RNX-051 in 2028E, with the remaining projects expected to launch in 2029-31E, and estimate probability-weighted peak sales in the range of DKK1.1-1.2bn. We model EBIT of up to negative DKK17m until estimated break-even in 2028E, when we forecast EBIT of DKK83m.
- Valuation. Our updated sum-of-the-parts valuation (WACC 12.5% unchanged) points to a fair value range of DKK0.30-0.76 per share (was DKK0.31-0.77 per share) on a 12M basis, reflecting the increased number of shares. A key driver is the royalty rate, where we estimate a tier-based rate of 12-20% of sales, averaging 15% across all pipeline projects.

Year-end Dec (DKK)	2022	2023	2024E	2025E	2026E					
Revenues (m)	0.0	0.0	0.0	25.0	50.0		MAN	A 'I 'I	A S	0
Revenues growth					100.0%	0.55		~~~~	vin	
EBITDA (m)	-4.3	-20.9	-22.5	-4.0	20.5	0.50	m	•	~	h
EBIT adj. (m)	-4.3	-20.9	-23.0	-4.5	20.0	0.40				
EBIT growth	n.m.	n.m.	-10.1%	80.4%	n.m.	0.35	AM			
Pre-tax profit (m)	3.5	-26.8	-28.1	-8.2	16.0	0.30 -	and the	an	4	
EPS adj.	0.24	-0.05	-0.02	-0.01	0.01	0.25 -	5	m 1	m	
						0.20 -	6			M.
DPS	0.00	0.00	0.00	0.00	0.00	0.15				\sim
Dividend yield										
FCFE yield (pre-IFRS16)	310.3%	-7.4%	-10.9%	-3.7%	3.0%	-PEGRP.CO	-MSCI Euro	pe/Pharma	aceuticals	rebase
EBIT margin (adj.)	n.m.	n.m.	n.m.	-18.0%	39.9%		1M	ЗM	12M	5Y
Net debt/EBITDA (x)	n.m.	n.m.	n.m.	n.m.	-0.5	Absolute	-12%	-33%	-59%	-929
ROIC	27.2%	-49.8%	-20.6%	-3.9%	16.0%	Rel. local market	-8%	-24%	-63%	-95%
EV/sales (x)	high	n.m.	n.m.	8.9	4.3	Rel. EU sector	-5%	-23%	-62%	-939
EV/EBITDA (adj.) (x)	n.m.	n.m.	n.m.	n.m.	10.5	1101. 20 300101	-370	2070	0270	33,
EV/EBITA (adj.) (x)	n.m.	n.m.	n.m.	n.m.	10.6					
EV/EBIT (adj.) (x)	n.m.	n.m.	n.m.	n.m.	10.8					
P/E (adj.) (x)	1.9	n.m.	n.m.	n.m.	17.7					

Source: Company data, Danske Bank Equity Research estimates

Source: FactSet

Q3 24 review

Pharma Equity Group reported Q3 24 earnings on 15 November 2024, with results overall in line with our expectations. The EBITDA loss of DKK5.1m was c.4% lower than our estimate, driven by lower R&D costs in the quarter, which were down 29% y/y but flat vs. Q2 24.

Administrative costs (SG&A) increased 8% y/y and came in above our expectations, with the growth in SG&A costs primarily driven by hirings as the company gears up for a potential partnership agreement in 2025.

Table 1. Q3 24 deviation table

	Actual	DBER	DIFF				
DKKm	Q3 24	Q3 24	(%)	Q3 23	Y/Y (%)	Q2 24	Q/Q (%)
Sales	0.0	0.0	NA	0.0	NA	0.0	NA
Cost of Sales	0.0	0.0	NA	0.0	NA	0.0	NA
Gross Profit	0.0	0.0	NA	0.0	NA	0.0	NA
R&D costs	-1.8	-2.5	-27%	-2.5	-29%	-1.8	-3%
SG&A costs	-3.5	-3.0	15%	-3.2	8%	-3.1	10%
EBITDA	-5.1	-5.3	-4%	-5.7	-10%	-4.9	5%
EBIT	-5.2	-5.5	-4%	-5.7	-8%	-5.0	5%
Financial items, net	-1.9	-1.5	31%	1.1	-275%	-1.3	49%
Pre-tax profit	-7.1	-6.9	4%	-4.6	54%	-6.3	14%
Taxes	0.4	1.0	-60%	0.2	71%	0.4	0%
Net profit or loss	-6.7	-5.9	14%	-4.4	54%	-5.9	15%

Source: Company data, Danske Bank Equity Research (DBER) estimates

The guidance for 2024 was kept unchanged, with revenue expected at DKK0m (DBER: DKK0m) and pre-tax profit at negative DKK24-29m (DBER: -DKK29m).

Pre-tax profit for the first nine months of 2024 was negative DKK21.2m. Management still aims for a partnership agreement in 2025, which it expects to generate milestone revenues.

Table 2. Guidance tracker

			2024		DIFF to
DKKm	2023 Actual	2024 guidance	Mid-range	DBER	mid-range
Revenue	0	0	0	0	0
Profit before tax	-27*	-24 to -29**	-27	-28	-2

* 2023 included a write-down of DKK4.4m related to the Portinho receivable ** For 2024, the expected loss does not reflect any gains/losses relating to the Portinho S.A. receivable. Source: Company data, Danske Bank Equity Research (DBER) estimates


Cash position


The company ended the quarter with DKK3.8m in cash and with approximately DKK5m in available unused credit facilities. In October 2024, the company raised DKK51m in gross proceeds, which will impact the Q4 24 report.

The capital raise included conversion of convertible debt of DKK13m and we estimate c.DKK2m in fees, leaving DKK36m in net proceeds. Pharma Equity Group has used the net proceeds to strengthen the balance sheet, with DKK26m being used to reduce financial debt, increasing the cash position by DKK13m.

The capital raise was fully subscribed by a limited group of new and existing shareholders, with a subscription price of DKK0.25 per share, corresponding to a premium of c.20% compared to the market price on 3 October 2024.








We model a cumulative cash burn of c.DKK12m (Q4 24 to FY27) before turning cash flow positive by 2028E, compared to current available liquidity of DKK19m, leaving a cash surplus of DKK7m.

We believe that the company might further tap markets, including with both equity and convertible debt, to accelerate its clinical pipeline and to fund operations until expected partnering in 2025, which we also covered in our initiation report from July 2024.

Chart 2. Projected capital requirements (DKKm)



Pipeline update

No updates to the pipeline, and we continue to believe that RNX-011 in peritonitis and RNX-051 in colorectal cancer, which are the furthest in clinical development, hold the largest potential in the company's pipeline. For RNX-011 we expect the ongoing formulation work to be completed by the end of 2024.

In October 2024, Reponex was granted a patent for RNX-051 in Japan, covering the treatment method of eliminating biofilms, with the patent being valid until 2039. Reponex now has patent protection for RNX-051 in both Europe and Japan.

Danske <mark>Bank</mark>

Indication	Candidate	Phase 1	Phase 2	Phase 3	Market	Clinical status
Peritonitis	RNX-011					Ph2b/3 ready
Colorectal cancer	RNX-051					Ph2b/3 ready
Pouchitis	RNX-041					Ph2, recruiting
Chronic skin ulcers	RNX-022					Ph2 ready
Infected chronic skin ulcers	RNX-023					Ph2 ready
Chronic skin ulcers	RNX-021					Ph2, not recruiting

The next catalysts for both pipeline projects are out-licensing agreements, and we expect the company to sign a partnership agreement before the end of 2025.

Area	Key milestones	Next step
RNX-011 (peritonitis/cLAI)	Phase 2a (12 patients), proof of concept was achieved in 2019/20.	Out-licensing partner.
	Non-clinical work ongoing to optimise formulation.	
RNX-051 (colorectal cancer)	Phase 2a (22 patients), proof of concept was achieved in April 2024 (MEFO study)	Out-licensing partner.
RNX-041	Recruitment ongoing for Phase 2 trial.	Read out in Q2 25
(pouchitis)		If positive, possible study in Crohn's disease / partner.
RNX-021/022/023 (chronic skin ulcers)	Ready for Phase 2 clinical development, but not recruiting.	Start recruiting and development after capital raise or out-licensing of other
	We believe that the company will focus its efforts on the other pipeline projects and postpone development of RNX-021/022/023 due to financial limitations.	pipeline projects.
Operations	Hiring of commercial relationships director to increase efforts to secure an out-licensing partner.	Engage with KOLs and secure partnerships.

Estimate changes

We make small estimates adjustment, primarily reflecting lower R&D costs but higher SG&A costs in 2024, which has a limited effect on EBITDA. We estimate slightly higher SG&A going forward.

Estimates

Table 4. Profit and loss statement estimates

P&L (DKKm)	2023	2024E	2025E	2026E	2027E	2028E	2029E	2030E	2031E	2032E
RNX-011 (Bacterial peritonitis)	0	0	0	0	0	11	22	46	71	99
RNX-051 (Colorectal cancer)	0	0	0	0	0	11	24	49	77	106
RNX-041 (Inflammatory bowel disease)	0	0	0	0	0	0	3	5	11	17
RNX-022 (Chronic skin ulcers)	0	0	0	0	0	0	0	6	20	41
RNX-023 (Chronic skin ulcers)	0	0	0	0	0	0	0	0	2	7
Milestones	0	0	25	50	25	100	30	23	23	C
Total sales	0	0	25	50	25	122	78	129	204	270
y/y growth (%)	n.m.	n.m.	n.m.	100%	-50%	388%	-36%	65%	58%	33%
COGS	0	0	0	0	0	0	0	0	0	C
Gross profit	0	0	25	50	25	122	78	129	204	270
Gross margin (%)	n.m.	n.m.	100%	100%	100%	100%	100%	100%	100%	100%
R&D and initial launch costs	9	9	14	13	16	19	22	27	32	39
Sales & Distribution costs	0	0	0	0	0	0	0	0	0	0
Admin costs	12	15	16	17	19	21	23	25	27	30
Total opex	21	23	30	30	34	39	45	52	60	69
y/y growth (%)	n.m.	10%	28%	2%	14%	15%	15%	15%	15%	15%
EBIT	-21	-23	-5	20	-9	83	33	77	144	201
EBIT margin (%)	n.m.	n.m.	n.m.	39.9%	n.m.	67.8%	42.3%	59.8%	70.6%	74.4%
Interest income	0	0	0	0	0	0	1	2	4	7
Interest expenses	-2	-5	-4	-4	-4	-4	-4	-4	-4	-4
Other financials	-4	0	0	0	0	0	0	0	0	C
Net financials	-6	-5	-4	-4	-4	-4	-3	-2	0	3
Pre-tax profit	-27	-28	-8	16	-13	79	30	76	143	204
Тах	2	4	2	-4	3	-17	-7	-17	-32	-45
Net profit	-25	-24	-6	13	-10	61	24	59	112	159

Investment case

Pharma Equity Group (PEG) is a Danish holding company with a 100% ownership of Reponex Pharmaceuticals (Reponex), a biotech company focused on repurposing already approved medicines for new purposes. The company continues its search for both commercial and R&D partnership for its pipeline of six drug candidates, which all are in clinical development. The company has already completed several of its smaller investigator and proof-of-concept studies. PEG is now on the lookout for R&D and commercial partnerships, like global university hospitals or pharmaceuticals companies, to conduct larger clinical trials to confirm the results from the smaller studies and potentially take the pipeline candidates to market. The company is solely focused on early clinical studies and will not be running any Phase 3 studies on its own due to the company's size and financial resources.

We believe that the pipeline studies, RNX-011 in peritonitis and RNX-051 in colorectal cancer, which are the furthest in clinical development, hold the largest potential in the company's pipeline.

Valuation and methodology for deriving of valuation range

We use a discounted cash flow (DCF) based sum-of-the-parts valuation, which is based on 20year forecasts from 2024-2043 and a 12.5% WACC.

Our updated SoTP now points to a fair value range of DKK0.30-0.76 per share (was DKK0.31-0.77 per share) on a 12M basis, reflecting slightly higher SG&A costs. In our base case we derive a fair value estimate of DKK0.49. We have only modelled and assigned NPV values to

studies in Phase 2, which means that we have not assigned any value to the new molecular entities (NMEs) in pre-clinical development, which are several years from clinical development.

We have not included the Portinho S.A. receivable in the SoTP, which offers further upside if paid in full. The book value of DKK58m, equalling DKK0.06 per share, offers upside of c.10% to our SoTP, with the total value of DKK80m equalling DKK0.08 per share, with c.14% upside to our SoTP if repaid in full.

Overhead costs reflect overhead costs of an average c.DKK41m per year until 2043.

We do not include any terminal value for PEG/Reponex.

				Peak	De-risked		Fair	
			Expected	sales	NPV per	Probabilit	value	NPV per
Compound	Indication	Phase	Launch	DKKm	share	У	DKKm	share
RNX-011	Bacterial	2	2028	4,309		25%	288	0.28
	peritonitis				1.11			
RNX-051	Colorectal cancer	2	2028	4,614	1.18	25%	307	0.30
RNX-041	Pouchitis	2	2029	1,048	0.20	20%	47	0.05
RNX-021, 022	Chronic skin	2	2030	3,305		15%	83	0.08
	ulcers				0.53			
RNX-023	Chronic skin	2	2031	1,171		15%	28	0.03
	ulcers				0.17			
Net cash/(debt)							11	0.01
Overhead costs							-169	-0.14
Fair value	WACC 12.5%						598	0.49

Table 5. Valuation summary sum-of-the-parts, base case

Valuation scenarios

As highlighted below, the royalty rate is highly sensitive for our model, with a bear case salesbased royalty rate of 10% suggesting a fair value of DKK373m (DKK0.30 per share), compared to DKK598m (DKK0.49 per share) in our base case (15% royalty rate) and DKK934m (DKK0.76 per share) in our bull case based on a 22.5% royalty rate.

Table 6. Valuation scenarios, NPV (DKKm)

Compound	Indication		Royalty rate	
		Bear case	Base case	Bull case
		(10%)	(15%)	(22.5%)
RNX-011	Bacterial peritonitis	200	288	421
RNX-051	Colorectal cancer	212	307	449
RNX-041	Inflammatory bowel disease	38	47	62
RNX-021, 022	Chronic skin ulcers	60	84	121
RNX-023	Chronic skin ulcers	21	28	38
Total		531	755	1,091
Net cash/(debt)		11	11	11
Overhead costs		-169	-169	-169
Fair value	WACC 12.5%	373	598	934
Fair value per share	9	0.30	0.49	0.76

Source: Danske Bank Equity Research estimates, Refinitiv

Figure 2. Sensitivity analysis, NAV per share (DKK)

				Royalt	y rate (% of	sales)		
		7.5%	10.0%	12.5%	15.0%	, 17.5%	20.0%	22.5%
	8.0%	0.34	0.48	0.63	0.78	0.92	1.07	1.22
	9.5%	0.29	0.41	0.54	0.66	0.79	0.91	1.04
с	11. 0 %	0.25	0.35	0.46	0.57	0.67	0.78	0.89
WACC	12.5%	0.21	0.30	0.40	0.49	0.58	0.67	0.76
3	14.0%	0.18	0.26	0.34	0.42	0.50	0.58	0.66
	15.5%	0.16	0.23	0.29	0.36	0.43	0.50	0.57
	17.0%	0.14	0.20	0.26	0.31	0.37	0.43	0.49

Source: Company data, Danske Bank Equity Research

Share price catalysts

For 2024 and beyond, we have listed the key potential share price catalysts in the table below. We believe that the main upside risks are partnership agreements and increased confidence in key pipeline assets.

Table 7. Expected news flow and catalysts

Announce partnership deal(s) to further support development of the pipeline. Repayment of Portinho receivable (c.DKK80m).	High High
Repayment of Portinho receivable (c.DKK80m).	High
	riigii
Ongoing non-clinical formulation optimisation.	Moderate
Phase 2 data readout in pouchitis.	High
Restart of paused trials at Bispebjerg Hospital, depending on financia resources available.	al Moderate
	Phase 2 data readout in pouchitis. Restart of paused trials at Bispebjerg Hospital, depending on financia

Source: Danske Bank Equity Research estimates

Risks to achievement of valuation range

Biotech is risky and PEG is no exception. Biotech investments are associated with considerably above-average risk, which include an investment in PEG. Its research projects may fail, or the company could run into liquidity problems if the expected revenues do not materialise.

Technology risk

A key risk factor when investing in biotech companies is the proprietary technology used to develop the drug candidates, as this could prove inadequate and stop the company from securing satisfactory clinical results and thus launching its product. PEG's clinical pipeline is based on repositioning already approved drugs, which lowers the technology risk.

Failure of pipeline candidates

PEG is not dependent on a single compound or technology for its clinical trials, but the share price is highly sensitive to the release of clinical data or delays in the development process. Clinical data from potentially competing products could also impact the value of the company.

Commercial risk

The company intends to out-license its clinical trials prior to the Phase 3 stage to large pharma companies with established commercial resources, thereby eliminating the need to market its own products. The primary risk involved in this strategy is the potential failure to secure any



partnership agreements, which could result in the company being left with suspended clinical trials.

Patents and exclusivity

The patent protection that covers the company pipeline studies are method-of-use patents, compared to the standard composition of matter patents given to new developed drugs that protect the drugs from generic competition. In our view, method-of-use patents are inherently weaker than composition of matter patents, as PEG's drug candidates are based on approved drugs with expired patents, and it is unclear how strong these patents are until they have been challenged in court.

Financial risk

PEG does not currently have any income to fund the development of the pipeline and therefore depends on investor funding. We believe the company will probably need additional funding from the market until it is profitable from expected future royalty income.

Biotech sentiment

If the economy suffers a downturn, liquidity is likely to tighten and the high-risk asset classes could fall out of favour, leading to tough times for biotech investments.



Company summary

Company information

www.pharmaequitygroup.com

Pharma Equity Group Slotsmarken 18, 2.th., 2970 Hørsholm

Denmark

EBIT and EBIT margin (DKKm)

25 20 15 10 5 -10 -15 -10 -15 -20 -25 -30

2019

2020 80

Name	Votes (%)	Capital (%)		
Finansmanagement ApS	16.6%	16.6%		
DMZ Holding ApS	7.6%	7.6%		

EBIT —EBIT margin (RHS)

50%

40%

30%

20%

10%

0%


-10%


-20%

-30%


2026E

024F 025E





P/E NTM(x)



Source: FactSet, Company data, Danske Bank Equity Research estimates

Click here for link to ESG webpage for all companies under coverage.

This report is for Thomas Kaas Selsø @ Pharma Equity Group A/S. Unauthorized redistribution of this report is prohibited.

Summary tables

INCOME STATEMENT Year end Dec, DKKm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
Net sales					0.0	0.0	0.0	0.0	0.0	25.
Cost of sales & operating costs					0.0	-1.4	-4.3	-20.9	-22.5	-29.
EBITDA					0.0	-1.4	-4.3	-20.9	-22.5	-4.
EBITDA, adj.								-20.9	-22.5	
-					0.0	-1.4	-4.3	-20.9		-4.
Depreciation									0.0	0.
EBITA					0.0	-1.4	-4.3	-20.9	-22.5	-4.
EBIT incl. EO, bef. ass.					0.0	-1.4	-4.3	-20.9	-23.0	-4.
EBIT, adj.					0.0	-1.4	-4.3	-20.9	-23.0	-4.
Associated income						4.8	5.8	-4.4		
Financial items, net	0.0	0.0	0.0	0.0	0.0	2.0	2.0	-1.5	-5.1	-3
Pre-tax profit					0.0	5.4	3.5	-26.8	-28.1	-8
Taxes								2.2	4.2	1
Net profit, rep.					0.0	5.4	3.5	-24.6	-23.9	-6
Net profit, adj.					0.0	5.4	3.5	-24.6	-23.9	-6
CASH FLOW										
DKKm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
EBITDA					0.0	-1.4	-4.3	-20.9	-22.5	-4
Change in working capital					1.9	34.8	-1.2	3.4	0.8	-1
Net interest paid					-0.2	-1.2	-0.7	-1.5	-5.1	-3
Taxes paid					4.2	5.5	5.5	1.9	4.9	1
Other operating cash items					6.7	9.6	21.3	0.6		
Cash flow from operations					12.6	47.2	20.5	-16.6	-21.9	-8
Capex					-1.7	-0.1	-0.2	-0.1	-0.1	-0
Div to min										
Free cash flow					11.0	47.0	20.4	-16.7	-22.0	-8
Disposals/(acquisitions)										
Free cash flow to equity					11.0	47.0	20.4	-16.7	-22.0	-8
Dividend paid										
Share buybacks										
New issue common stock					43.7	155	61.9	8.3	36.5	
Incr./(decr.) in debt					88.9	10.4	7.9	-99.4	-7.8	3
Minorities & other financing CF					-107	4.8	-185	-47.0	7.0	0
Cash flow from financing					25.5	170	-115	-138	28.7	3
•					25.5	170	-115	-130	20.7	3
Disc. ops & other										
Incr./(decr.) in cash					36.4	217	-94.4	-155	6.7	-4.
BALANCE SHEET										
DKKm	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
Cash & cash equivalents					36.4	253	159	4.2	10.9	6
Inventory										5
Trade receivables					15.6	13.5	8.8	63.0	63.0	63
Other current assets										
Goodwill										
Other intangible assets					16.6	16.6	16.6	13.6	13.1	12
Fixed tangible assets					0.2	1.2	1.0	0.1	0.1	0
Associated companies							0.2	-4.2	-4.2	-4
Other non-current assets					0.1	0.3	0.3	0.5	0.5	0
Total assets					68.9	285	186	77.1	83.4	83
Shareholders' equity					-58.4	49.4	-27.7	38.9	51.5	45
Of which minority interests									22	
Current liabilities					32.3	64.9	76.6	34.3	35.1	38
nterest-bearing debt					88.9	99.3	107	7.8	00.1	3
-					00.5	33.3	107	1.0		-
Pension liabilities					C 1	74.4	00.0	~ ~	~ ~	
Oth non-curr. liabilities					6.1	71.4	29.6	0.2	0.9	0
Total liabilities					127	236	213	42.4	36.1	42
Total liabilities and equity					68.9	-154	-51.8	81.3 3.6	-10.9	87
Net debt					52.5					

Summary tables

PER SHARE DATA	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
No. of shares, fully diluted (y.e.) (m)	1,227.5	1,227.5			995.7	6.5	22.2	1,023.0	1,227.5	1,227.
No. of shares, fully diluted (avg.) (m)	3,682.6	1,227.5	613.8		995.7	501.1	14.3	522.6	1,125.2	1,227
EPS (DKK)	0.00	0.00	0.00		0.00	0.01	0.24	-0.05	-0.02	-0.
EPS adj. (DKK)	0.00	-0.20	0.00		0.00	0.01	0.24	-0.05	-0.02	-0.
DPS (DKK)	0.00	0.00			0.00	0.00	0.00	0.00	0.00	0.
CFFO/share (DKK)	0.0	0.0	0.0		0.0	0.1	1.4	-0.0	-0.0	-0
Book value/share (DKK)	0.00	0.00			-0.06	7.61	-1.25	0.04	0.04	0.0
MARGINS AND GROWTH	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
EBITDA margin					n.m.	n.m.	n.m.	n.m.	n.m.	-16.1
EBITA margin					n.m.	n.m.	n.m.	n.m.	n.m.	-16.1
EBIT margin					n.m.	n.m.	n.m.	n.m.	n.m.	-18.0
EBIT adj margin					n.m.	n.m.	n.m.	n.m.	n.m.	-18.0
Sales growth										
EBITDA growth							n.m.	n.m.	-7.7%	82.1
EBITA growth							n.m.	n.m.	-7.7%	82.1
EPS adj growth			100.0%				n.m.	n.m.	54.9%	75.5
PROFITABILITY	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
ROIC (after tax, incl. GW, adj.)					0.0%	8.0%	27.2%	-49.8%	-20.6%	-3.9
ROIC (after tax, excl. GW, adj.)					0.0%	8.0%	27.2%	-49.8%	-20.6%	-3.9
ROE (adj.)					0.0%	-119.6%	32.1%	-437.8%	-52.8%	-13.2
ROIC (adj.) - WACC					-12.5%	-4.5%	14.7%	-62.3%	-33.1%	-16.4
MARKET VALUE	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
Share price (DKK)				1.83	0.94	0.56	0.46	0.43	0.18	0.
No. shares reduced by buybacks (m)	1,227.5	1,227.5			995.7	6.5	22.2	1,023.0	1,227.5	1,227
Mkt cap used in EV (m)					938	4	10	440	221	2
Net debt, year-end (m)					52	-154	-52	4	-11	
MV of min/ass and oth (m)					0	0	-0	4	4	
Enterprise value (m)					991	n.m.	n.m.	448	214	23
VALUATION	2016	2017	2018	2019	2020	2021	2022	2023	2024E	2025
EV/sales (x)					n.m.	high	high	n.m.	n.m.	8.
EV/EBITDA (x)					n.m.	n.m.	n.m.	n.m.	n.m.	n.i
EV/EBITA (x)					n.m.	n.m.	n.m.	n.m.	n.m.	n.i
EV/EBIT (x)					n.m.	n.m.	n.m.	n.m.	n.m.	n.i
P/E (reported) (x)					n.m.	52.1	1.9	n.m.	n.m.	n.i
P/E (adj.) (x)					n.m.	52.1	1.9	n.m.	n.m.	n.i
P/BV (x)					n.m.	0.07	n.m.	11.3	4.29	4.
EV/invested capital (x)					14.0	n.m.	n.m.	5.1	2.5	2
Dividend yield										
Total yield (incl. buybacks)										
FCFE-yield					1.17%	1,293.50%	200.54%	-3.80%	-9.95%	-3.69
FINANCIAL RATIOS	2016	2017	2018	2019	2020	2021	2022	2023	2024E	202
Net debt/EBITDA (x)	n.m.	n.m.	n.m.	n.m.	high	n.m.	n.m.	n.m.	n.m.	n.i
Net debt/equity (x), year-end					-0.9	-3.1	1.9	0.1	-0.2	-0
Dividend payout ratio	n.m.	n.m.			n.m.	0.0%	0.0%	0.0%	0.0%	0.0
Interest coverage (x)					n.m.	-0.0	1.9	n.m.	-97.3	n.
Cash conversion (FCF/net profit)					n.m.	872.4%	585.0%	n.m.	n.m.	n.
Capex/sales					n.m.	n.m.	n.m.	n.m.	n.m.	0.3
NWC/sales					n.m.	n.m.	n.m.	n.m.	n.m.	118.8
QUARTERLY P&L			Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24
Sales (m)			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0
EBITDA (m)			-3.4	-4.9	-5.7	-6.8	-6.7	-4.9	-5.1	-5
EBIT before non-recurring items (m)			-3.4	-4.9	-5.7	-6.8	-6.8	-5.0	-5.2	-5
Net profit (adj.) (m)			-2.9	-4.3	-4.4	-13.0	-7.2	-5.9	-6.7	-4
EPS (adj.) (DKK)			0.00	0.00	0.00	-0.01	-0.01	-0.01	-0.01	0.
EBITDA margin			n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.
EBIT margin (adj.)			n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.m.	n.i

Disclosures

This commissioned research report has been prepared by Equity Research, a division of Danske Bank A/S ('Danske Bank'). The authors of this research report are Thomas Bowers and Tobias Nissen.

This commissioned research report should be considered marketing material, as it has been requested and paid for by Pharma Equity Group and has therefore not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, the report is still subject to prohibition on dealing ahead of the dissemination of the report.

Analyst certification

Each research analyst responsible for the content of this commissioned research report certifies that the views expressed in the research report accurately reflect the research analyst's personal view about the financial instruments and issuers covered by the research report.

Regulation

Danske Bank is authorised and regulated by the Danish Financial Services Authority (Finanstilsynet). Danske Bank is authorised by the Prudential Regulation Authority in the UK and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request.

Danske Bank's commissioned research reports are prepared in accordance with the recommendations of Capital Market Denmark.

Conflicts of interest

Danske Bank has established procedures to prevent conflicts of interest and to ensure the provision of high-quality research based on research objectivity and independence from outside influences. These procedures are documented in Danske Bank's research policies. Employees within Danske Bank's Research Departments have been instructed that any request that might impair the objectivity of research and independence from outside influence of research shall be referred to Research Management and the Compliance Department. Danske Bank's Research Departments are physically separated from other business areas within Danske Bank and surrounded by arrangements (Chinese Walls) to restrict the flows of sensitive information.

Research analysts are remunerated in part based on the overall profitability of Danske Bank, which includes investment banking revenues, but do not receive bonuses or other remuneration linked to specific corporate finance or debt capital transactions.

Danske Bank, its affiliates, subsidiaries and staff may perform services for or solicit business from Pharma Equity Group and may hold long or short positions in, or otherwise be interested in, the financial instruments mentioned in this research report. The Equity and Corporate Bonds analysts of Danske Bank and persons in other departments of Danske Bank with which the relevant analysts have close links are not permitted to invest in 1) financial instruments that are covered by the relevant Equity or Corporate Bonds analyst and 2) the research sector within the geographical area (the Nordics) to which the analyst is linked.

Danske Bank, its affiliates and subsidiaries are engaged in commercial banking, securities underwriting, dealing, trading, brokerage, investment management, investment banking, custody and other financial services activities, may be a lender to Pharma Equity Group and have whatever rights as are available to a creditor under applicable law and the applicable loan and credit agreements. At any time, Danske Bank, its affiliates and subsidiaries may have credit or other information regarding Pharma Equity Group that is not available to or may not be used by the personnel responsible for the preparation of this report, which might affect the analysis and opinions expressed in this research report.

Danske Bank is a market maker and a liquidity provider and may hold positions in the financial instruments of the issuer(s) mentioned in this research report.

No parts of this research report have been disclosed to Pharma Equity Group for factual check.

As an investment bank, Danske Bank, its affiliates and subsidiaries provide a variety of financial services, including investment banking services. It is possible that Danske Bank and/or its affiliates and/or its subsidiaries might seek to become engaged to provide such services to Pharma Equity Group in the next three months.

Financial models and/or methodology used in this research report

Investment views and opinions in this research report are formed on the basis of a combined selection of discounted cash flow analysis, industry knowledge, peer group analysis and company-specific and market technical elements (events affecting both the financial and operational profile of the company). Forecasting of company sales and earnings is based on segmented bottom-up models using subjective views of relevant future market developments. In addition, the expected macroeconomic environment is taken into account. The output is aggregated into models for group profil and loss, balance sheets and cash flow estimates – all taking into account the recent development in historical research reports.

More information about the valuation and/or methodology and the underlying assumptions is accessible via www.danskebank.com/equityresearch.

Risk warning

Major risks connected with investment views or opinions in this research report, including a sensitivity analysis of relevant assumptions, are stated throughout the text.

Expected updates

This research product will be updated on a semi-annual basis as a minimum.

Completion and first dissemination

The completion date and time in this research report mean the date and time when the author hands over the final version of the research report to Danske Bank's editing function for legal review and editing.

The date and time of first dissemination mean the date and estimated time of the first dissemination of this research report. The estimated time may deviate up to 15 minutes from the effective dissemination time due to technical limitations.

See the back page of this research report for the date and time of first dissemination.

Recommendation structure

This report does not have a target price or a buy/sell recommendation but it does include a valuation discussion and a suggested valuation range.

Validity time period

This communication as well as previous communications referred to below are valid until the earlier of (a) dissemination of a superseding communication by the author, or (b) significant changes in circumstances following its dissemination, including events relating to the market or the issuer, which can influence the price of the issuer or financial instrument.

General disclaimer

This commissioned research report has been prepared by Danske Bank A/S. It is provided for informational purposes only and should not be considered investment, legal or tax advice. It does not constitute or form part of, and shall under no circumstances be considered as, an offer to sell or a solicitation of an offer to purchase or sell any relevant financial instruments (i.e. financial instruments mentioned herein or other financial instruments of any issuer mentioned herein and/or options, warrants, rights or other interests with respect to any such financial instruments) ('Relevant Financial Instruments').

This commissioned research report has been prepared independently and solely on the basis of publicly available information that Danske Bank A/S considers to be reliable but Danske Bank A/S has not independently verified the contents hereof. While reasonable care has been taken to ensure that its contents are not untrue or misleading, no representation or warranty, express or implied, is made as to and no reliance should be placed on the fairness, accuracy, completeness or reasonableness of the information, opinions and projections contained in this commissioned research report and Danske Bank A/S, its affiliates and subsidiaries accept no liability whatsoever for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this commissioned research report.

The opinions expressed herein are the opinions of the research analysts and reflect their opinion as of the date hereof. These opinions are subject to change and Danske Bank A/S does not undertake to notify any recipient of this research report of any such change nor of any other changes related to the information provided in this commissioned research report.

This commissioned research is not intended for, and may not be redistributed to, retail customers in the United Kingdom and may under no circumstances be distributed in the United States.

This research report is protected by copyright and is intended solely for the designated addressee. It may not be reproduced or distributed, in whole or in part, by any recipient for any purpose without Danske Bank A/S's prior written consent.

Disclaimer related to distribution in the United Kingdom

In the United Kingdom, this document is for distribution only to (I) persons who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); (II) high net worth entities falling within article 49(2)(a) to (d) of the Order; or (III) persons who are an elective professional client or a per se professional client under Chapter 3 of the FCA Conduct of Business Sourcebook (all such persons together being referred to as 'Relevant Persons'). In the United Kingdom, this document is directed only at Relevant Persons, and other persons should not act or rely on this document or any of its contents.

Disclaimer related to distribution in the European Economic Area

This document is being distributed to and is directed only at persons in member states of the European Economic Area ('EEA') who are 'Qualified Investors' within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) ('Qualified Investors'). Any person in the EEA who receives this document will be deemed to have represented and agreed that it is a Qualified Investor. Any such recipient will also be deemed to have represented and agreed that it has not received this document to behalf of persons in the EEA other than Qualified Investors or persons in the UK and member states (where equivalent legislation exists) for whom the investor has authority to make decisions on a wholly discretionary basis. Danske Bank A/S will rely on the truth and accuracy of the foregoing representations and agreements. Any person in the EEA who is not a Qualified Investor should not act or rely on this document or any of its contents.

Report completed: 17 November 2024 at 15:35 CET Report disseminated: 18 November 2024 at 07:00 CET